|
1.
|
Sorimachi H, Ishiura S and Suzuki K:
Structure and physiological function of calpains. Biochem J.
328:721–732. 1997.
|
|
2.
|
Goll DE, Thompson VF, Li H, Wei W and Cong
J: The calpain system. Physiol Rev. 83:731–801. 2002. View Article : Google Scholar
|
|
3.
|
Ono Y, Sorimachi H and Suzuki K: Structure
and physiology of calpain, an enigmatic protease. Biochem Biophys
Res Commun. 245:289–294. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Maki M, Ma H, Takano E, Adachi Y, Lee WJ,
Hatanaka M and Murachi T: Calpastatins: biochemical and molecular
biological studies. Biomed Biochim Acta. 50:509–516.
1991.PubMed/NCBI
|
|
5.
|
Carragher NO: Calpain inhibition: a
therapeutic strategy targeting multiple disease states. Curr Pharm
Des. 12:615–638. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Sharma RK: Purification and
characterization of novel calmodulin-binding protein from cardiac
muscle. J Biol Chem. 265:1152–1157. 1990.PubMed/NCBI
|
|
7.
|
Kakkar R, Raju RV, Mellgren RL, Radhi J
and Sharma RK: Cardiac high molecular weight calmodulin binding
protein contains calpastatin activity. Biochemistry.
36:11550–11555. 1997. View Article : Google Scholar
|
|
8.
|
Carragher NO and Frame MC: Calpain: a role
in cell transformation and migration. Int J Biochem Cell Biol.
34:1539–1543. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Huttenlocher A, Palecek SP, Lu Q, Zhang W,
Mellgren RL, Lauffenburger DA, Ginsberg MH and Horwitz AF:
Regulation of cell migration by the calcium-dependent protease
calpain. J Biol Chem. 272:32719–32722. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Patel YM and Lane MD: Mitotic clonal
expansion during pre-adipocyte differentiation: calpain-mediated
turnover of p27. J Biol Chem. 275:17653–17660. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Lakshmikuttyamma A, Selvakumar P, Kakkar
R, Kanthan R, Wang R and Sharma RK: Activation of calcineurin
expression in ischemia-reperfused rat heart and in human ischemic
myocardium. J Cell Biochem. 90:987–997. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Lakshmikuttyamma A, Selvakumar P, Sharma
AR, Anderson DH and Sharma RK: In vitro proteolytic degradation of
bovine brain calcineurin by m-calpain. Neurochem Res. 29:1913–1921.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Lakshmikuttyamma A, Selvakumar P,
Charavaryamath C, Singh B, Tuchek J and Sharma RK: Expression of
calcineurin and its interacting proteins in epileptic fowl. J
Neurochem. 96:366–373. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Lakshmikuttyamma A, Selvakumar P, Tuchek J
and Sharma RK: Myristoyltransferase and calcineurin: novel
molecular therapeutic target for epilepsy. Prog Neurobiol.
84:77–84. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Selvakumar P, Lakshmikuttyamma A,
Charavaryamath C, Singh B, Tuchek J and Sharma RK: Expression of
myristoyltransferase and its interacting proteins in epilepsy.
Biochem Biophys Res Commun. 335:1132–1139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Kishimoto A, Kajikawa N, Shiota M and
Nishizuka Y: Preoteolytic activation of calcium-activated,
phospholipid-dependent protein kinase by calcium-dependent neutral
protease. J Biol Chem. 258:1156–1164. 1983.
|
|
17.
|
Oda A, Drucker BJ, Ariyoshi H, Smith M and
Salzman E: pp60src is an andogenous substrate for
calpain in human blood platelets. J Biol Chem. 268:12603–12608.
1993.
|
|
18.
|
Frangioni JV, Oda A, Smith M, Salzman EW
and Neel BG: Calpain-catalyzed cleavage and subcellular relocation
of protein phosphotyrosine phosphatase 1B PTB-1B in human
platelets. EMBO J. 12:4843–4856. 1993.
|
|
19.
|
Braun C, Engel M, Seifert M, Theisinger B,
Seitz G, Zang KD and Welter C: Expression of calpain I messenger
RNA in human renal cell carcinoma: correlation with lymph node
metastasis and histological type. Int J Cancer. 84:6–9. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Mamoune A, Luo JH, Lauffenburger DA and
Wells A: Calpain-2 is a target for limiting prostate cancer
invasion. Cancer Res. 63:4632–4640. 2003.PubMed/NCBI
|
|
21.
|
Yoshikawa Y, Mukai H, Hino F, Asada K and
Kato I: Isolation of two novel genes, down regulated in gastric
cancer. Jpn J Cancer Res. 91:459–463. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Liu K, Li L and Cohen SN: Antisense
RNA-mediated deficiency of the calpain protease, nCL-4, in
NH3T3cells is associated with neoplastic transformation and
tumorigenesis. J Biol Chem. 275:31093–31098. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Witkowski JM, Zmuda-Trzebiatowska E,
Swiercz JM, Cichorek M, Ciepluch H, Lewandowski K, Bryl E and
Hellmann A: Modulation of the activity of calcium-activated neutral
proteases calpains in chronic lymphocytic leukemia B-CLL cells.
Blood. 100:1802–1809. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Carillo S, Pariat M, Steff AM, Roux P,
Etienne-Julan M, Lorca T and Piechaczyk M: Differential sensitivity
of FOS and JUN family members to calpains. Oncogene. 9:1679–1689.
1994.PubMed/NCBI
|
|
25.
|
Kubbutat MH and Vousden KH: Proteolytic
cleavage of human p53 by calpain: a potential regulator of protein
stability. Mol Cell Biol. 17:460–468. 1997.PubMed/NCBI
|
|
26.
|
Carragher NO, Fincham VJ, Riley D and
Frame MC: Cleavage of focal adhesion kinase by different proteases
during SRC-regulated transformation and apoptosis. Distinct roles
for calpain and caspases. J Biol Chem. 276:4270–4275. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Johnson D, Frame MC and Wyke JA:
Expression of the v-Src oncoprotein in fibroblasts disrupts normal
regulation of the CDK inhibitor p27 and inhibits quiescence.
Oncogene. 16:2017–2028. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Kellie S: Cellular transformation,
tyrosine kinase oncogenes and the cellular adhesion plaque.
Bioessays. 8:25–30. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Carragher NO, Westhoff MA, Riley D, Potter
DA, Dutt P, Elce JS, Greer PA and Frame MC: v-Src-induced
modulation of the calpain-calpastatin proteolytic system regulates
transformation. Mol Cell Biol. 22:257–269. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Bolen JB, Veillette A, Schwartz AM, DeSeau
V and Rosen N: Activation of pp60c-src protein kinase
activity in human colon carcinoma. Proc Natl Acad Sci USA.
84:2251–2255. 1987.PubMed/NCBI
|
|
31.
|
Ottenhoff-Kalff AE, Rijksen G, van Beurden
EA, Hennipman A, Michels AA and Staal GE: Characterization of
protein tyrosine kinases from human breast cancer: involvement of
the c-src oncogene product. Cancer Res. 52:4773–4778.
1992.PubMed/NCBI
|
|
32.
|
Lakshmikuttyamma A, Selvakumar P, Kanthan
R, Kanthan SC and Sharma RK: Overexpression of m-calpain in human
colorectal adenocarcinomas. Cancer Epidemiol Biomarkers Prev.
13:1604–1609. 2004.PubMed/NCBI
|
|
33.
|
Selvakumar P, Smith-Windsor E, Bonham K
and Sharma RK: N-myristoyltransferase 2 expression in human colon
cancer: cross-talk between the calpain and caspase system. FEBS
Lett. 580:2021–2026. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Raju RV, Kakkar R, Datla RS, Radhi J and
Sharma RK: Myristoyl-coA: protein N-myristoyltransferase from
bovine cardiac muscle: molecular cloning, kinetic analysis and in
vitro proteolytic cleavage by m-calpain. Exp Cell Res. 241:23–35.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Giaccia AJ and Kastan MB: The complexity
of p53 modulation: emerging patterns from divergent signals. Genes
Dev. 12:2973–2983. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Gonen H, Shkedy D, Barnoy S, Kosower NS
and Ciechanover A: On the involvement of calpains in the
degradation of the tumor suppressor protein p53. FEBS Lett.
406:17–22. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Toyota H, Yanase N, Yoshimoto T, Moriyama
M, Sudo T and Mizuguchi J: Calpain-induced Bax-cleavage product is
a more potent inducer of apoptotic cell death than wild-type Bax.
Cancer Lett. 189:221–230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Blomgren K, Zhu C, Wang X, Karlsson JO,
Leverin AL, Bahr BA, Mallard C and Hagberg H: Synergistic
activation of caspase-3 by m-calpain after neonatal
hypoxia-ischemia: a mechanism of ‘pathological apoptosis’? J Biol
Chem. 276:10191–10198. 2001.PubMed/NCBI
|
|
40.
|
Ruiz-Vela A, Gonzalez de Buitrago G and
Martinez AC: Implication of calpain in caspase activation during B
cell clonal deletion. EMBO J. 18:4988–4998. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Chen T, Yang I, Irby R, Shain KH, Wang HG,
Quackenbush J, Coppola D, Cheng JQ and Yeatman TJ: Regulation of
caspase expression and apoptosis by adenomatous polyposis coli.
Cancer Res. 63:4368–4374. 2003.PubMed/NCBI
|
|
42.
|
Zhu DM and Uckun FM: Calpain inhibitor II
induces caspase-dependent apoptosis in human acute lymphoblastic
leukemia and non-Hodgkin's lymphoma cells as well as some solid
tumor cells. Clin Cancer Res. 6:2456–2463. 2000.PubMed/NCBI
|
|
43.
|
Raju RV, Moyana TN and Sharma RK:
N-myristoyltransferase overexpression in human colorectal
adenocarcinomas. Exp Cell Res. 235:145–154. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Moyana TN and Xiang J: Expression of
tumor-associated polymorphic epithelial mucin and carcinoembryonic
antigen in gastrointestinal carcinoid tumors. Cancer. 75:2836–2843.
1995. View Article : Google Scholar
|
